Establishment and characterization of liver-specific Apoa4-Cre and Cyp2c11-Cre rat models in juvenile and adult stages

Abstract

Background: Liver diseases are a major contributor to both morbidity and mortality. Conditional knockout animals are always produced through crossing floxed animals with a tissue-specific Cre animal. The use of floxed rat resource has rapidly increased, but the liver-specific Cre rat lines for studying liver diseases and interested genes are limited, especially in a spatially and temporally restricted manner.

Methods: RNA sequencing and real-time polymerase chain reaction (PCR) were used to screen and confirm the presence of liver-specific genes. Apoa4-Cre rats and Cyp2c11-Cre rats were produced by CRISPR/Cas9 knockin. Rosa26-imCherry rats were employed to hybridize with the Cre rats to obtain the Apoa4-Cre/Rosa26-imCherry and Cyp2c11-Cre/Rosa26-imCherry rats. The temporal and spatial patterns of Cre expression were determined by the observation of red fluorescence on tissue sections. Hematoxylin–eosin stain was used to evaluate the liver histopathologic changes. The blood biochemical analysis of several liver enzymes and liver lipid profile was performed to evaluate the liver function of Cre rats.

Results: Apoa4 and Cyp2c11 were identified as two liver-specific genes. Apoa4-Cre and Cyp2c11-Cre rats were produced and hybridized with Rosa26-imCherry rats. The red fluorescence indicated that the Cre recombinases were specially expressed in the juvenile and adult liver and not in other organs of two hybridized rats. All the blood biochemical parameters except low-density lipoprotein (LDL) did not change significantly in the Cre rats. No histological alterations were detected in the livers of the Cre rats.

Conclusions: Liver-specific Apoa4-Cre and Cyp2c11-Cre rats have been established successfully and could be used to study gene knockout, specifically in juvenile and adult liver.

Keywords

Apoa4 / Cre / Cyp2c11 / liver / rat

References

[1] Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017; 27(21): R1147-R1151.

[2] Rui L. Energy metabolism in the liver. Compr Physiol. 2014; 4(1): 177-197.

[3] Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013; 14(10): 996-1006.

[4] Bleibel W, Kim S, D'Silva K, Lemmer ER. Drug-induced liver injury: review article. Dig Dis Sci. 2007; 52(10): 2463-2471.

[5] Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014; 60(6): 2099-2108.

[6] Zeng F, Zhang Y, Han X, Weng J, Gao Y. Liver buds and liver organoids: new tools for liver development, disease and medical application. Stem Cell Rev Rep. 2019; 15(6): 774-784.

[7] Prior N, Inacio P, Huch M. Liver organoids: from basic research to therapeutic applications. Gut. 2019; 68(12): 2228-2237.

[8] Tsuneyama K, Nishitsuji K, Matsumoto M, et al. Animal models for analyzing metabolic syndrome-associated liver diseases. Pathol Int. 2017; 67(11): 539-546.

[9] Wei W, Dirsch O, Lawson Mclean A, Zafarnia S, Schwier M, Dahmen U. Rodent models and imaging techniques to study liver regeneration. Eur Surg Res. 2015; 54(3-4): 97-113.

[10] Martin M, Motolani A, Kim HG, et al. KDM2A deficiency in the liver promotes abnormal liver function and potential liver damage. Biomolecules. 2023; 13(10): 1457.

[11] Ma Y, Zhang X, Shen B, et al. Generating rats with conditional alleles using CRISPR/Cas9. Cell Res. 2014; 24(1): 122-125.

[12] Chenouard V, Remy S, Tesson L, et al. Advances in genome editing and application to the generation of genetically modified rat models. Front Genet. 2021; 12: 615491.

[13] Cho T, Wierk A, Gertsenstein M, Rodgers CE, Uetrecht J, Henderson JT. The development and characterization of a CRISPR/Cas9-mediated PD-1 functional knockout rat as a tool to study idiosyncratic drug reactions. Toxicol Sci. 2024; 198(2): 233-245.

[14] Iannaccone PM, Jacob HJ. Rats! Dis Model Mech. 2009; 2(5-6): 206-210.

[15] Ma Y, Chen W, Zhang X, et al. Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing in rats by inhibiting NHEJ and using Cas9 protein. RNA Biol. 2016; 13(7): 605-612.

[16] Ma Y, Yu L, Pan S, et al. CRISPR/Cas9-mediated targeting of the Rosa26 locus produces Cre reporter rat strains for monitoring Cre-loxP-mediated lineage tracing. FEBS J. 2017; 284(19): 3262-3277.

[17] Sato Y, Endo H, Ajiki T, et al. Establishment of Cre/LoxP recombination system in transgenic rats. Biochem Biophys Res Commun. 2004; 319(4): 1197-1202.

[18] Shimoyama M, Smith JR, Bryda E, Kuramoto T, Saba L, Dwinell M. Rat genome and model resources. ILAR J. 2017; 58(1): 42-58.

[19] Liu Z, Brown A, Fisher D, Wu Y, Warren J, Cui X. Tissue specific expression of Cre in rat tyrosine hydroxylase and dopamine active transporter-positive neurons. PLoS One. 2016; 11(2): e0149379.

[20] Bryda EC, Men H, Davis DJ, et al. A novel conditional ZsGreen-expressing transgenic reporter rat strain for validating Cre recombinase expression. Sci Rep. 2019; 9(1): 13330.

[21] Song J, Xu Y, Hu X, Choi B, Tong Q. Brain expression of Cre recombinase driven by pancreas-specific promoters. Genesis. 2010; 48(11): 628-634.

[22] Wang F, Kohan AB, Lo CM, Liu M, Howles P, Tso P. Apolipoprotein A-IV: a protein intimately involved in metabolism. J Lipid Res. 2015; 56(8): 1403-1418.

[23] Duverger N, Tremp G, Caillaud JM, et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 1996; 273(5277): 966-968.

[24] Khovidhunkit W, Duchateau PN, Medzihradszky KF, et al. Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. Atherosclerosis. 2004; 176(1): 37-44.

[25] Gomez P, Perez-Martinez P, Marin C, et al. APOA1 and APOA4 gene polymorphisms influence the effects of dietary fat on LDL particle size and oxidation in healthy young adults. J Nutr. 2010; 140(4): 773-778.

[26] Guclu-Geyik F, Onat A, Coban N, et al. Minor allele of the APOA4 gene T347S polymorphism predisposes to obesity in postmenopausal Turkish women. Mol Biol Rep. 2012; 39(12): 10907-10914.

[27] Wei Y, Yang L, Zhang X, et al. Generation and characterization of a CYP2C11-null rat model by using the CRISPR/Cas9 method. Drug Metab Dispos. 2018; 46(5): 525-531.

[28] Choi HK, Waxman DJ. Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression. Endocrinology. 2000; 141(9): 3245-3255.

[29] Ye H, Sui D, Liu W, Yuan Y, Ouyang Z, Wei Y. Effects of CYP2C11 gene knockout on the pharmacokinetics and pharmacodynamics of warfarin in rats. Xenobiotica. 2019; 49(12): 1478-1484.

[30] Li J, Li MR, Sun B, et al. Inhibition of rat CYP1A2 and CYP2C11 by honokiol, a component of traditional Chinese medicine. Eur J Drug Metab Pharmacokinet. 2019; 44(6): 787-796.

[31] Zhu J, DeLuca HF. Vitamin D 25-hydroxylase - four decades of searching, are we there yet? Arch Biochem Biophys. 2012; 523(1): 30-36.

[32] Rahmaniyan M, Patrick K, Bell NH. Characterization of recombinant CYP2C11: a vitamin D 25-hydroxylase and 24-hydroxylase. Am J Physiol Endocrinol Metab. 2005; 288(4): E753-E760.

[33] Liu W, Sui D, Ye H, Ouyang Z, Wei Y. CYP2C11 played a significant role in down-regulating rat blood pressure under the challenge of a high-salt diet. PeerJ. 2019; 7: e6807.

[34] Huang Y, Qin J, Sun D, et al. Inhibition of soluble epoxide hydrolase reduces portal pressure by protecting mesenteric artery myogenic responses in cirrhotic rats. Prostaglandins Other Lipid Mediat. 2017; 131: 17-24.

[35] Pouyabahar D, Chung SW, Pezzutti OI, et al. A rat liver cell atlas reveals intrahepatic myeloid heterogeneity. iScience. 2023; 26(11): 108213.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.